_________
false
C003
áéåìééï àø à÷ñ áò"î
2
Public
BIOLINE RX LTD
9253
Corporation no:
513398750
Stock Exchange/Market:
NASDAQ CM
2271
381
HaMa'ayan
2
,
Modi'in
7177871
,
,
Israel
Tel:
08-6429100
,
Fax:
08-6429101
E.mail address:
info@BioLineRx.com
Reported via MAGNA:
28/06/2016
Time of broadcast:
13:48
13:38:54
Company site:
www.biolinerx.com
Reference:
2016-02-068407
Israel Securities Authority
Tel Aviv Stock Exchange
www.isa.gov.il
www.tase.co.il
Other Report or Announcement
Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
6-K_BL8040_280616_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
2016-02-008722
Previous names of reporting entity:
Date of revision of form structure:
08/06/2016
Name of the Signatory:
:
Kotler Norman Harold
,
Position of Signatory in the reporting corporation:
General Counsel & Company Secretary
,
Name of Employer Company:
.
Hartum
19
Jerusalem
9777518
Telephone:
02-5489100
,
Facsimile:
02-5489101
,
E-mail:
normank@biolinerx.com
1